Those findings are supportive of previously published data that suggest that low ERBB2 expression is not associated with CDK4/6i benefit15,16 and that it is not a distinct entity in breast cancer by clinical factors assessed so far.13,17. The gene discussed is ERBB2; the disease is breast carcinoma.